A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors

NCT06681870 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped A business decision was made to not initiate this study.

Conditions

CLDN6-positive Solid Tumor
Ovarian Cancer
Endometrial Cancer
Non-small Cell Lung Cancer
Testicular Cancer
Metastatic or Locally Advanced Solid Tumor Cancer

Interventions

DRUG: ASP1893

Sponsor

Astellas Pharma Global Development, Inc.